AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38269534 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone health coaching with remote exercise monitoring (TeGeCoach; n = 994)
Number of subjects: 1982
Study 38269534 — intervention group
Group type: COMPARATOR
Intervention: Routine care (n = 988)
Number of subjects: 1982
Study 38270079 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary aldosteronism (PA) with ARR ≥ 1.0
Number of subjects: 0
Study 38270079 — intervention group
Group type: COMPARATOR
Intervention: Essential hypertension with ARR ≥ 1.0
Number of subjects: 0
Study 38270079 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk based on ARR
Number of subjects: 0
Study 38270079 — intervention group
Group type: EXPERIMENTAL
Intervention: ARR cutoff setting
Number of subjects: 0
Study 38270182 — intervention group
Group type: EXPERIMENTAL
Intervention: S-LMA
Number of subjects: 510
Study 38270219 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Number of subjects: 0
Study 38270219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 38270219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 38270814 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-physician communication regarding fatigue
Number of subjects: 1179
Study 38270814 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy, radiotherapy, or immunotherapy
Number of subjects: 1179
Study 38270814 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age and major depression
Number of subjects: 1179
Study 38270814 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication barriers
Number of subjects: 1179
Study 38270814 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician appreciation and handling of fatigue-related questions
Number of subjects: 1179
Study 38270822 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax 150 mg daily plus Sorafenib 400 mg twice daily
Number of subjects: 25
Study 38270822 — intervention group
Group type: COMPARATOR
Intervention: Navitoclax alone
Number of subjects: 25
Study 38270954 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 562
Study 38270954 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 562
Study 38271019 — intervention group
Group type: EXPERIMENTAL
Intervention: TranS-C group treatment
Number of subjects: 152
Study 38271079 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI + SFAS
Number of subjects: 132
Study 38271079 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI + RT
Number of subjects: 132
Study 38271079 — intervention group
Group type: COMPARATOR
Intervention: BMI + SFAS and BMI + RT
Number of subjects: 132
Study 38271299 — intervention group
Group type: COMPARATOR
Intervention: Informational counselling (IC) only
Number of subjects: 38
Study 38271299 — intervention group
Group type: EXPERIMENTAL
Intervention: IC with hearing aid fitting
Number of subjects: 38
Study 38271299 — intervention group
Group type: EXPERIMENTAL
Intervention: IC with individualized music stimulation for 12 months
Number of subjects: 38
Study 38271308 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Assessment Guide (OAG) assessment
Number of subjects: 88
Study 38271308 — intervention group
Group type: COMPARATOR
Intervention: Patients 60 months or younger
Number of subjects: 88
Study 38271308 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of diuretics
Number of subjects: 88
Study 38271308 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of oral care
Number of subjects: 88
Study 38271308 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale score
Number of subjects: 88
Study 38271308 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial respiration
Number of subjects: 88
Study 38271311 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning
Number of subjects: 32
Study 38271320 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VR
Number of subjects: 90
Study 38271320 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive VR
Number of subjects: 90
Study 38271320 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 90
Study 38271621 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP followed by (R)-ICE
Number of subjects: 151
Study 38271621 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP followed by (R)-ICE (propensity score-matched patients from MSK)
Number of subjects: 151
Study 38271621 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (matched MER cohort)
Number of subjects: 151
Study 38271925 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoceranib 685 mg once daily (Part 2)
Number of subjects: 61
Study 38271925 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoceranib 805 mg once daily (Part 3)
Number of subjects: 61
Study 38271925 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivoceranib (Part 1)
Number of subjects: 61
Study 38272050 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised short-course antibiotic treatment (≤7 days, as short as 3-5 days)
Number of subjects: 461
Study 38272050 — intervention group
Group type: COMPARATOR
Intervention: Usual care (≥8 days, with precise durations determined by primary clinicians)
Number of subjects: 461
Study 38272050 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course treatment
Number of subjects: 461
Study 38272050 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 461
Study 38272116 — intervention group
Group type: EXPERIMENTAL
Intervention: TBRI Caregiver Curriculum, TBRI Youth & Young Adult Curriculum, TBRI Nurture Groups (delivered while youth are in residential facilities)
Number of subjects: 0
Study 38272116 — intervention group
Group type: EXPERIMENTAL
Intervention: TBRI Family Coaching Curriculum (delivered after youth transition home)
Number of subjects: 0
Study 38272118 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosing Recovery intervention
Number of subjects: 50
Study 38272118 — intervention group
Group type: COMPARATOR
Intervention: Comparator condition (attention-control)
Number of subjects: 50
Study 38272247 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with ILD
Number of subjects: 112
Study 38272247 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 112
Study 38272046 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (2 g/kg, single dose)
Number of subjects: 237
Study 38272046 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (10 mg/kg per day for 3 consecutive days)
Number of subjects: 237
Study 38272046 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab (12 mg/kg for patients <30 kg; 8 mg/kg for patients ≥30 kg, max 800 mg)
Number of subjects: 237
Study 38272046 — intervention group
Group type: COMPARATOR
Intervention: Anakinra (2 mg/kg once per day for patients ≥10 kg)
Number of subjects: 237
Study 38272046 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care (no additional treatments)
Number of subjects: 237
Study 38272376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 38272376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in QUEST)
Number of subjects: 0
Study 38272373 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment in patients with biallelic pathogenic FLG variants
Number of subjects: 285
Study 38272373 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment in patients with monoallelic pathogenic FLG variants or wild-type alleles
Number of subjects: 285
Study 38272375 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab 100/200 mg by body weight or volume-matched placebo every 2 weeks for 52 weeks
Number of subjects: 408
Study 38272375 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 408
Study 38272375 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 408
Study 38272383 — intervention group
Group type: EXPERIMENTAL
Intervention: PPOS protocol (Medroxyprogesterone 10 mg daily from start of ovarian stimulation until ovulation trigger)
Number of subjects: 784
Study 38272383 — intervention group
Group type: COMPARATOR
Intervention: Antagonist protocol (Antagonist 0.25 mg daily from the sixth day of ovarian stimulation until ovulation trigger)
Number of subjects: 784
Study 38272383 — intervention group
Group type: EXPERIMENTAL
Intervention: PPOS protocol (per-protocol analysis)
Number of subjects: 784
Study 38272383 — intervention group
Group type: COMPARATOR
Intervention: Antagonist protocol (per-protocol analysis)
Number of subjects: 784
Study 38272391 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturelysis after trabeculectomy
Number of subjects: 15
Study 38272555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cholesterol (600 mg)/low-saturated fat (6%) (egg) diet
Number of subjects: 52
Study 38272555 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cholesterol (300 mg)/high-saturated fat (12%) (egg free) diet
Number of subjects: 52
Study 38272555 — intervention group
Group type: COMPARATOR
Intervention: Control diet that is high in both cholesterol (600 mg) and saturated fat (12%)
Number of subjects: 52
Study 38272561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 32
Study 38272561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 32
Study 38272571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nerinetide
Number of subjects: 421
Study 38272571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 38272776 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote delivery (RD) of weight management intervention
Number of subjects: 120
Study 38272776 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face (FTF) weight management intervention
Number of subjects: 120
Study 38272892 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cTBS intervention
Number of subjects: 39
Study 38272892 — intervention group
Group type: COMPARATOR
Intervention: Sham cTBS intervention
Number of subjects: 39
Study 38272958 — intervention group
Group type: EXPERIMENTAL
Intervention: RECO device
Number of subjects: 268
Study 38273019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) administered as a monthly, 3-days course for three consecutive months
Number of subjects: 2340
Study 38273019 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 2340
Study 38273019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 2340
Study 38273044 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative evaluation by echocardiography and inflammatory proteins
Number of subjects: 75
Study 38273214 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Treatment Score post-5 years (CTS5)
Number of subjects: 2114
Study 38273214 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing continuous CTS5
Number of subjects: 2114
Study 38273214 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged endocrine therapy (ET) for high-risk patients
Number of subjects: 2114
Study 38273214 — intervention group
Group type: EXPERIMENTAL
Intervention: CTS5
Number of subjects: 2114
Study 38273252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen
Number of subjects: 158
Study 38273252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen plus acetaminophen
Number of subjects: 158
Study 38273252 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 158
Study 38273259 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet clothing removal and wrapping in a vapor barrier, insulating blankets, and windproof outer shell (dry group)
Number of subjects: 0
Study 38273259 — intervention group
Group type: COMPARATOR
Intervention: Wrapping in a vapor barrier, insulating blankets, and windproof outer shell (wet group)
Number of subjects: 0
Study 38273259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 38273290 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IPF
Number of subjects: 300
Study 38273296 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) - excitatory (20 min @ 10 Hz, applied to the lateral and medial pre-frontal cortex)
Number of subjects: 0
Study 38273296 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) - inhibitory (20 min @ 1 Hz, applied to the pelvic supplemental motor area)
Number of subjects: 0
Study 38273296 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned in the abstract.
Number of subjects: 0
Study 38273300 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients perceived as dying
Number of subjects: 696
Study 38273300 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on the day of death
Number of subjects: 696
Study 38273300 — intervention group
Group type: COMPARATOR
Intervention: Patients with dementia at admission
Number of subjects: 696
Study 38273319 — intervention group
Group type: EXPERIMENTAL
Intervention: PLUS algorithm (clinical prediction score, lung ultrasound (LUS), procalcitonin (PCT), clinical severity score)
Number of subjects: 10
Study 38273319 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10
Study 38273319 — intervention group
Group type: EXPERIMENTAL
Intervention: PLUS algorithm
Number of subjects: 10
Study 38273369 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-Trainer (TT)
Number of subjects: 125
Study 38273369 — intervention group
Group type: COMPARATOR
Intervention: Train-the-Trainer plus ongoing consultation for trainers (TT +)
Number of subjects: 125
Study 38273369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of implementation for TT
Number of subjects: 125
Study 38273369 — intervention group
Group type: COMPARATOR
Intervention: Cost of implementation for TT +
Number of subjects: 125
Study 38273370 — intervention group
Group type: EXPERIMENTAL
Intervention: Consequences Of Screening Lung Cancer (COS-LC) questionnaire administered at prespecified timepoints including at enrolment, dependent on screening results.
Number of subjects: 1129
Study 38273370 — intervention group
Group type: EXPERIMENTAL
Intervention: COS-LC questionnaire
Number of subjects: 1129
Study 38273379 — intervention group
Group type: EXPERIMENTAL
Intervention: Alantel cream (natural products at high concentrations)
Number of subjects: 88
Study 38273379 — intervention group
Group type: COMPARATOR
Intervention: Moisturizing cream (control)
Number of subjects: 88
Study 38273393 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oxygen delivery targeting a blood oxygen saturation of 88-92% during inhalation therapy
Number of subjects: 1888
Study 38273393 — intervention group
Group type: COMPARATOR
Intervention: Standard high flow oxygen delivery
Number of subjects: 1888
Study 38273390 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout during the pandemic measured by the Shirom-Melamed Burnout Measure
Number of subjects: 954
Study 38273390 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and research activities during the pandemic
Number of subjects: 954
Study 38273390 — intervention group
Group type: EXPERIMENTAL
Intervention: Training resources during the pandemic
Number of subjects: 954
Study 38273390 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in COVID-19 management
Number of subjects: 954
Study 38273390 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout among trainees
Number of subjects: 954
Study 38273408 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg per day of oral CT1812 for 24 weeks
Number of subjects: 23
Study 38273408 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg per day of oral CT1812 for 24 weeks
Number of subjects: 23
Study 38273408 — intervention group
Group type: COMPARATOR
Intervention: 100 mg or 300 mg per day of oral CT1812 for 24 weeks
Number of subjects: 23
Study 38273408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 38273436 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hemodialysis
Number of subjects: 0
Study 38273597 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 219
Study 38273597 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 219
Study 38273597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially assigned)
Number of subjects: 219
Study 38273617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (1 min once daily)
Number of subjects: 14
Study 38273617 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (1 min four times daily)
Number of subjects: 14
Study 38273617 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (device implanted but not activated)
Number of subjects: 14
Study 38273624 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-55920839 (0.3-15 mg/kg IV or 1 mg/kg SC)
Number of subjects: 76
Study 38273624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 38273625 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilimab 180 mg
Number of subjects: 44
Study 38273625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 38273637 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib 5 mg twice daily plus placebo
Number of subjects: 180
Study 38273637 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily plus methotrexate
Number of subjects: 180
Study 38273639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus 2 mg once daily
Number of subjects: 44
Study 38273639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 38273712 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive program
Number of subjects: 279
Study 38273712 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic program
Number of subjects: 279
Study 38273712 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 279
Study 38274114 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 or 100 μg rTSST-1v
Number of subjects: 140
Study 38274114 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg rTSST-1v
Number of subjects: 140
Study 38274114 — intervention group
Group type: COMPARATOR
Intervention: Al(OH)
Number of subjects: 140
Study 38274233 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic endonasal surgery (EES)
Number of subjects: 211
Study 38274236 — intervention group
Group type: EXPERIMENTAL
Intervention: ARNI
Number of subjects: 539
Study 38274236 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2i
Number of subjects: 539
Study 38274236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (ARNI + SGLT2i)
Number of subjects: 539
Study 38274236 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 539
Study 38274236 — intervention group
Group type: EXPERIMENTAL
Intervention: ARNI (alone)
Number of subjects: 539
Study 38274292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) administered to the left dorsolateral prefrontal cortex (DLPFC) for 14 days every 13 weeks
Number of subjects: 42
Study 38274292 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 42
Study 38274389 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 Gy SCRT in five fractions
Number of subjects: 172
Study 38274398 — intervention group
Group type: EXPERIMENTAL
Intervention: Velacur®
Number of subjects: 143
Study 38274414 — intervention group
Group type: EXPERIMENTAL
Intervention: SPL026 (21.5 mg) administered as a 2-phase IV infusion over 10 minutes (6 mg/5 min and 15.5 mg/5 min)
Number of subjects: 0
Study 38274414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38274492 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF 25 mg/day with selgantolimod 3 mg orally once weekly (QW)
Number of subjects: 67
Study 38274492 — intervention group
Group type: EXPERIMENTAL
Intervention: Selgantolimod 1.5 mg QW
Number of subjects: 67
Study 38274492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 38274807 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical concurrent chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy, followed by adjuvant immunotherapy for at least one year.
Number of subjects: 0
Study 38274885 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable home-use gait device (iStride), 12 sessions of 30 minutes each
Number of subjects: 18
Study 38274885 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable home-use gait device (iStride)
Number of subjects: 18
Study 38275115 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid moderate-to-severe SDB and AF
Number of subjects: 353
Study 38275115 — intervention group
Group type: COMPARATOR
Intervention: AF without moderate-to-severe SDB
Number of subjects: 353
Study 38275116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenecteplase
Number of subjects: 1577
Study 38275116 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase
Number of subjects: 1577
Study 38275650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 183
Study 38275650 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 183
Study 38276920 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported fair or poor oral health
Number of subjects: 2
Study 38276933 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal perfusion system
Number of subjects: 173
Study 38277156 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipod insulin delivery system
Number of subjects: 0
Study 38277161 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural-Net Artificial Pancreas
Number of subjects: 0
Study 38277161 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 38277162 — intervention group
Group type: EXPERIMENTAL
Intervention: Macronutrient Intake and Number of Meals
Number of subjects: 0
Study 38277162 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38277197 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered ankle-foot device with device-specific rehabilitation intervention (Group A)
Number of subjects: 30